公开(公告)号：WO2007120008A1

公开(公告)日：2007-10-25

申请号：PCT/KR2007/001869

申请日：2007-04-17

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  YANG, Hyun Ok ,  YOO, Ji-Hye ,  KIM, Young-Joo ,  KIM, Su-Jeong ,  SUH, Jong-Teak ,  JUNG, Sang Hoon ,  CHA, Kwang-Hyun ,  KIM, Su-Nam ,  NHO, Chu Won ,  LEE, Saet Byoul ,  MOON, Kil Choo

Inventor： YANG, Hyun Ok ,  YOO, Ji-Hye ,  KIM, Young-Joo ,  KIM, Su-Jeong ,  SUH, Jong-Teak ,  JUNG, Sang Hoon ,  CHA, Kwang-Hyun ,  KIM, Su-Nam ,  NHO, Chu Won ,  LEE, Saet Byoul ,  MOON, Kil Choo

IPC: A61K36/287

CPC classification number: A61K36/287

Abstract: The present invention relates to use of the extract of Chrysanthemum zawadskii that is extracted using water, alcohol or a mixture thereof. Particularly, the extract of Chrysanthemum zawadskii can be used for an ant i- hangover agent because it can reduce alcohol density and acetaldehyde density in blood by promoting in vivo alcohol metabolism through improving activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), and present radical removal ability. The extract of Chrysanthemum zawadskii of the present invention can be used as an anti -hangover agent and health food for removing hangover because it can get rid of hangover more efficiently than hangover removing beverages in the market.

Abstract translation: 本发明涉及使用水，醇或其混合物提取菊苣提取物的用途。 特别地，菊花提取物可用于蚂蚁中毒剂，因为它可以通过改善醇脱氢酶（ADH）和乙醛脱氢酶（ALDH）的活性来促进体内酒精代谢，从而降低血液中的酒精密度和乙醛密度， 并具有根本的清除能力。 本发明的菊花提取物可以用作抗脱水剂和用于去除宿醉的保健食品，因为它可以比在市场上去除饮料的宿醉更有效地摆脱宿醉。

公开(公告)号：WO2009066876A2

公开(公告)日：2009-05-28

申请号：PCT/KR2008/006275

申请日：2008-10-23

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  YANG, Hyun Ok ,  KWON, Hak Cheol ,  PARK, Hyun-Bong ,  YOO, Ji-Hye

Inventor： YANG, Hyun Ok ,  KWON, Hak Cheol ,  PARK, Hyun-Bong ,  YOO, Ji-Hye

IPC: C12N1/20

CPC classification number: C12R1/66 ,  A23L29/065 ,  A23L33/10 ,  A23L33/135 ,  C12N1/14 ,  C12N1/20 ,  C12P17/182 ,  C12P17/185 ,  C12P39/00 ,  C12R1/01

Abstract: The present invention relates to a co-culture method of Sphingomonas sp. bacterial strain and Aspergillus sp. fungus strain, in which the novel Sphingomonas sp. bacterial strain KMK-001 is cultured in a liquid medium and the novel Aspergillus sp. strain KMC-901 separately cultured in another liquid medium is added to the above culture solution, a novel glionitrin biosynthesized therefrom and a pharmaceutical composition comprising the said glionitrin or its pharmaceutically acceptable salt as an active ingredient. The glionitrin herein has strong cytotoxic effect on cancer cells and has antibiotic effect on 10 pathogenic bacteria including the novel Sphingomonas sp. bacterial strain KMK-001, so that it can be effectively applied in antibiotics or anti-cancer agents.

Abstract translation: 本发明涉及鞘氨醇单胞菌（Sphingomonas sp。）的共培养方法。 细菌菌株和曲霉菌属。 真菌菌株，其中新型鞘氨醇单胞菌属 将细菌菌株KMK-001在液体培养基中培养，并将新型曲霉属菌株 在另一种液体培养基中分别培养的菌株KMC-901加入到上述培养液中，由其生物合成新的glionitrin以及包含所述glionitrin或其药学上可接受的盐作为活性成分的药物组合物。 本发明的glionitrin对癌细胞具有强烈的细胞毒性作用，并且对包括新型鞘氨醇单胞菌属在内的10种致病菌具有抗生素作用。 细菌菌株KMK-001，因此可以有效应用于抗生素或抗癌药物。

公开(公告)号：EP2209887A2

公开(公告)日：2010-07-28

申请号：EP08851184.5

申请日：2008-10-23

Applicant: Korea Institute of Science and Technology

Inventor： YANG, Hyun Ok ,  KWON, Hak Cheol ,  PARK, Hyun-Bong ,  YOO, Ji-Hye

IPC: C12N1/20

CPC classification number: C12R1/66 ,  A23L29/065 ,  A23L33/10 ,  A23L33/135 ,  C12N1/14 ,  C12N1/20 ,  C12P17/182 ,  C12P17/185 ,  C12P39/00 ,  C12R1/01

Abstract: The present invention relates to a co-culture method of Sphingomonas sp. bacterial strain and Aspergillus sp. fungus strain, in which the novel Sphingomonas sp. bacterial strain KMK-001 is cultured in a liquid medium and the novel Aspergillus sp. strain KMC-901 separately cultured in another liquid medium is added to the above culture solution, a novel glionitrin biosynthesized therefrom and a pharmaceutical composition comprising the said glionitrin or its pharmaceutically acceptable salt as an active ingredient. The glionitrin herein has strong cytotoxic effect on cancer cells and has antibiotic effect on 10 pathogenic bacteria including the novel Sphingomonas sp. bacterial strain KMK-001, so that it can be effectively applied in antibiotics or anti-cancer agents.